These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7149055)

  • 21. Urinary tryptamine excretion in chronic schizophrenics with low platelet MAO activity.
    Sullivan JL; Coffey CE; Basuk B; Cavenar JO; Maltbie AA; Zung WW
    Biol Psychiatry; 1980 Feb; 15(1):113-20. PubMed ID: 7357050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet monamine oxidase in chronic schizophrenia. Some enzyme characteristics relevant to reduced activity.
    Murphy DL; Donnelly CH; Miller L; Wyatt RJ
    Arch Gen Psychiatry; 1976 Nov; 33(11):1377-81. PubMed ID: 985048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of monoamine oxidase by high molecular weight fractions of human plasma.
    Wahlund LO; Sääf J; Ross SB; Wetterberg L
    Acta Physiol Scand; 1984 Mar; 120(3):337-41. PubMed ID: 6741571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substrate-typic changes of platelet monoamine oxidase activity in sub-types of schizophrenia.
    Demisch L; von der Mühlen H; Bochnik HJ; Seiler N
    Arch Psychiatr Nervenkr (1970); 1977 Dec; 224(4):319-29. PubMed ID: 606205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet monoamine oxidase activity in schizophrenia. Relationship to disease, treatment, institutionalization and outcome.
    Mann J; Thomas KM
    Br J Psychiatry; 1979 Apr; 134():366-71. PubMed ID: 36192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders.
    Orsulak PJ; Schildkraut JJ; Schatzberg AF; Herzog JM
    Biol Psychiatry; 1978 Dec; 13(6):637-47. PubMed ID: 737252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet monoamine oxidase activity in neuroleptic-naive schizophrenic patients: lack of influence of chronic perphenazine treatment.
    Spivak B; Kosower N; Zipser Y; Shreiber-Schul N; Apter A; Tyano S; Weizman A
    Clin Neuropharmacol; 1994 Feb; 17(1):83-8. PubMed ID: 8149362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients.
    Meltzer HY; Duncavage MB; Jackman H; Arora RC; Tricou BJ; Young M
    Am J Psychiatry; 1982 Oct; 139(10):1242-8. PubMed ID: 6127035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients.
    Meltzer HY; Arora RC; Jackman H; Pscheidt G; Smith MD
    Schizophr Bull; 1980; 6(2):213-9. PubMed ID: 7375852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of neuroleptics on platelet monoamine oxidase activity.
    Ho BT; Smith RC; Kralik P; Allen R; Schoolar J; Khan M; DeJohn C
    Biol Psychiatry; 1982 Aug; 17(8):885-95. PubMed ID: 6126230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients.
    Schildkraut JJ; Herzog JM; Orsulak PJ; Edelman SE; Shein HM; Frazier SH
    Am J Psychiatry; 1976 Apr; 133(4):438-40. PubMed ID: 1267046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further studies on the endogenous inhibitor of monoamine oxidase in schizophrenic plasma.
    Vogel WH; Ladman RK; Berrettini WH
    Schizophr Bull; 1980; 6(2):232-4. PubMed ID: 7375855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine-beta-hydroxylase, monoamine oxidase, and schizophrenia.
    DeLisi LE; Wise CD; Potkin SG; Zalcman S; Phelps BH; Lovenberg W; Wyatt RJ
    Biol Psychiatry; 1980 Dec; 15(6):895-907. PubMed ID: 7459411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet MAO Vmax and Km in chronic schizophrenic subjects.
    Giller EL; Bierer L; Rubinow D; Docherty JP
    Am J Psychiatry; 1980 Jan; 137(1):97-8. PubMed ID: 7352569
    [No Abstract]   [Full Text] [Related]  

  • 35. Human platelet MAO in drug-free and medicated schizophrenic patients.
    Friedhoff AJ; Miller JC; Weisenfreund J
    Am J Psychiatry; 1978 Aug; 135(8):952-5. PubMed ID: 27104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients.
    Meltzer HY; Stahl SM
    Res Commun Chem Pathol Pharmacol; 1974 Feb; 7(2):419-31. PubMed ID: 4594367
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of plasma from premenstrual syndrome and control patients on human platelet and rat brain synaptosome monoamine oxidase B activity.
    Ashby CR; Carr LA; Cook C; Steptoe MM; Franks DD
    Neuropsychobiology; 1992; 25(3):121-5. PubMed ID: 1407477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of nomifensine on platelet monoamine oxidase activity in chronic schizophrenic patients.
    Filinger EJ
    Gen Pharmacol; 1989; 20(6):821-2. PubMed ID: 2591711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and in schizoaffective patients.
    Joseph MH; Owen F; Baker HF; Bourne RC
    Psychol Med; 1977 Feb; 7(1):159-62. PubMed ID: 859953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet monoamine oxidase activity: relation to genetic load of schizophrenia.
    Baron M; Levitt M
    Psychiatry Res; 1980 Sep; 3(1):69-74. PubMed ID: 6934558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.